This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Magnetic Resonance (MR) Spectroscopy of Breast Cancer Tissue

This study is currently recruiting participants.
See Contacts and Locations
Verified August 2017 by Norwegian University of Science and Technology
Sponsor:
Collaborators:
The Research Council of Norway
The Norwegian Women´s Public Health Association
Information provided by (Responsible Party):
Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:
NCT00184210
First received: September 12, 2005
Last updated: August 17, 2017
Last verified: August 2017
September 12, 2005
August 17, 2017
January 2000
December 2020   (Final data collection date for primary outcome measure)
MRimage of breast cancer tissue [ Time Frame: 0 hour ]
Not Provided
Complete list of historical versions of study NCT00184210 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Magnetic Resonance (MR) Spectroscopy of Breast Cancer Tissue
HR MAS MR Spectroscopy of Breast Cancer Tissue

Breast cancer tissue is collected from women undergoing scheduled surgery for breast cancer. The tissue specimen are analyzed by MR spectroscopy. After MR, the intact tissue specimen can be analyzed by other methods, such as histopathology.

The MR spectral profiles are compared to clinical findings such as the patients diagnosis, lymph node status and tumor size.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples With DNA
Description:
tissue
Non-Probability Sample
women in surgery for breast cancer
Breast Neoplasms
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1000
December 2020
December 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Palpable breast cancer lesion
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact: Beathe Sitter, PhD +47 73 55 13 53 beathesi@ntnu.no
Contact: Tone F Bathen, PhD +47 73 86 38 44 tone.bathen@ntnu.no
Norway
 
 
NCT00184210
154080/I30
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Norwegian University of Science and Technology
Norwegian University of Science and Technology
  • The Research Council of Norway
  • The Norwegian Women´s Public Health Association
Study Chair: Tone F Bathen, PhD Norwegian University of Technology and Science
Norwegian University of Science and Technology
August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP